A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
← catalyst calendarNCT07717840 · readout in 57 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
160estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-08 | actual | When the study began enrolling |
| Primary completion | 2026-10-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- RSV Respiratory Syncytial Virus
Interventions
- Biological: AZD6489
- Biological: Licensed RSV vaccine #1
- Biological: Licensed RSV vaccine #2
Primary outcomes
what the primary-completion date above is the date OFIncidence of immediate unsolicited adverse events (AEs)
measured 30 minutes post-study intervention
Incidence of injection site and systemic solicited adverse reactions (ARs)
measured Day 1 through 7 days post-study intervention
Incidence of unsolicited adverse events (AEs)
measured Day 1 through 28 days post-study intervention
Incidence of serious adverse events (SAEs)
measured Day 1 to Day 365
Incidence of adverse events of special interest (AESIs)
measured Day 1 to Day 365
Incidence of medically attended adverse events (MAAEs)
measured Day 1 to Day 365
RSV A nAb responses to AZD6489
measured Day 29
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed